Free Trial

Dyne Therapeutics (DYN) Stock Price, News & Analysis

Dyne Therapeutics logo
$13.38 +0.38 (+2.88%)
Closing price 03:59 PM Eastern
Extended Trading
$13.38 0.00 (0.00%)
As of 04:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Dyne Therapeutics Stock (NASDAQ:DYN)

Key Stats

Today's Range
$12.86
$13.50
50-Day Range
$8.18
$13.00
52-Week Range
$6.36
$46.26
Volume
1.96 million shs
Average Volume
2.63 million shs
Market Capitalization
$1.90 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.07
Consensus Rating
Buy

Company Overview

Dyne Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
75th Percentile Overall Score

DYN MarketRank™: 

Dyne Therapeutics scored higher than 75% of companies evaluated by MarketBeat, and ranked 251st out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Dyne Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.06, and is based on 11 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Dyne Therapeutics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Dyne Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Dyne Therapeutics are expected to decrease in the coming year, from ($3.44) to ($3.62) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Dyne Therapeutics is -3.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Dyne Therapeutics is -3.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Dyne Therapeutics has a P/B Ratio of 2.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Dyne Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    13.35% of the float of Dyne Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Dyne Therapeutics has a short interest ratio ("days to cover") of 5.4.
  • Change versus previous month

    Short interest in Dyne Therapeutics has recently increased by 3.69%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Dyne Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Dyne Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.35% of the float of Dyne Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Dyne Therapeutics has a short interest ratio ("days to cover") of 5.4.
  • Change versus previous month

    Short interest in Dyne Therapeutics has recently increased by 3.69%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Dyne Therapeutics has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Dyne Therapeutics this week, compared to 7 articles on an average week.
  • Search Interest

    4 people have searched for DYN on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • MarketBeat Follows

    Only 5 people have added Dyne Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -38% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Dyne Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $911,000.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    20.77% of the stock of Dyne Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    96.68% of the stock of Dyne Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Dyne Therapeutics' insider trading history.
Receive DYN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DYN Stock News Headlines

Think you missed gold’s boom? Think again
If you've been watching gold's historic run and wondering if it's too late… I've got good news. Because there's a $15 fund tied directly to gold's surge that's still paying massive income… Up to 64% annually — with payouts every 30 days.tc pixel
See More Headlines

DYN Stock Analysis - Frequently Asked Questions

Dyne Therapeutics' stock was trading at $23.56 at the beginning of the year. Since then, DYN stock has decreased by 43.5% and is now trading at $13.31.

Dyne Therapeutics, Inc. (NASDAQ:DYN) announced its earnings results on Monday, July, 28th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($0.99) by $0.02.

Dyne Therapeutics (DYN) raised $175 million in an initial public offering (IPO) on Thursday, September 17th 2020. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel served as the underwriters for the IPO.

Top institutional shareholders of Dyne Therapeutics include TCG Crossover Management LLC (2.65%), Braidwell LP (2.30%), Adage Capital Partners GP L.L.C. (2.24%) and JPMorgan Chase & Co. (2.17%). Insiders that own company stock include Venture Fund Xi LP Atlas, Joshua T Brumm, John Cox, Oxana Beskrovnaya, Wildon Farwell, Jonathan Mcneill, Susanna Gatti High, Richard William Scalzo, Dirk Kersten, Johanna Friedl-Naderer and Carlo Incerti.
View institutional ownership trends
.

Shares of DYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Dyne Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
7/28/2025
Today
8/26/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:DYN
Previous Symbol
NYSE:DYN
CIK
1818794
Employees
100
Year Founded
N/A

Price Target and Rating

High Price Target
$50.00
Low Price Target
$9.00
Potential Upside/Downside
+162.1%
Consensus Rating
Buy
Rating Score (0-4)
3.06
Research Coverage
16 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.86)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$317.42 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-64.12%
Return on Assets
-56.75%

Debt

Debt-to-Equity Ratio
0.17
Current Ratio
16.83
Quick Ratio
16.83

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.19 per share
Price / Book
2.10

Miscellaneous

Outstanding Shares
142,260,000
Free Float
112,716,000
Market Cap
$1.85 billion
Optionable
Optionable
Beta
1.08

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:DYN) was last updated on 8/26/2025 by MarketBeat.com Staff
From Our Partners